EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats

Yudai Tsuruno, Ayaka Nagano, Koshiro Sugita, Shun Onishi, Yumiko Tabata, Chihiro Kedoin, Masakazu Murakami, Keisuke Yano, Takafumi Kawano, Nao Hasuzawa, Masatoshi Nomura, Tatsuru Kaji und 2 weitere

Pediatric Surgery International · 2024

DOI: 10.1007/s00383-024-05858-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Surgery International, 2024. Verfasst von Yudai Tsuruno und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Medical and Dental Area, Research and Education Assembly, Research Field in Medical and Health Sciences, Kagoshima U…. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Disease Models, Animal, Fatty Liver, Clodronic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kagoshima University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study investigated the anti-inflammatory effect of clodronate, a vesicular nucleotide transporter (VNUT) inhibitor, on intestinal-failure-associated liver disease (IFALD) in a rat model of short bowel syndrome (SBS).

Methods

The rats underwent jugular vein catheterization for continuous total parenteral nutrition (TPN) and 90% small bowel resection. The animals were divided into the following groups: TPN/SBS (Control group), TPN/SBS/intravenous administration of low-dose clodronate (20 mg/kg twice per week; Low group), or TPN/SBS/intravenous administration of high-dose clodronate (60 mg/kg twice per week; High group). On day 7, the rats were euthanized. Hepatic steatosis and hepatocellular injury were also assessed.

Results

Hepatic steatosis and lobular inflammation in the liver were observed in all groups. The High group showed histologically reduced hepatic steatosis compared with the Control group. IL-6 and Nlrp3 expression in the High group was significantly suppressed compared to that in the Control group. The expression of other inflammatory cytokines tended to be lower in the High dose group than in the control group. The lipid metabolism gene expression in the liver specimens showed no significant differences among the groups.

Conclusion

The high-dose administration of clodronate may, therefore, inhibit hepatic steatosis and inflammation associated with IFALD in patients with SBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Short Bowel SyndromeDisease Models, AnimalFatty LiverClodronic AcidAnimalsRatsMaleRats, Sprague-DawleyLiver

Stichwörter der Autor:innen

ClodronateHepatic steatosisIntestinal failure-associated liver diseaseShort bowel syndromeVNUT inhibitor

Substanzen

Clodronic Acid

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Medical and Dental Area, Research and Education Assembly, Research Field in Medical and Health Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
  • Division of Pediatric Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Pediatric Surgery, Medical and Dental Area, Research and Education Assembly, Research Field in Medical and Health Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. ksugita@m.…
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Department of Pediatric Surgery, Kurume University School of Medicine, Kurume, Japan.

Förderung

  • Kagoshima University

Zitieren

APA

Tsuruno, Y., Nagano, A., Sugita, K., Onishi, S., Tabata, Y., Kedoin, C., Murakami, M., Yano, K., Kawano, T., Hasuzawa, N., Nomura, M., Kaji, T., Bitoh, Y., & Ieiri, S. (2024). Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats. Pediatric Surgery International. https://doi.org/10.1007/s00383-024-05858-y

Vancouver

Tsuruno Y, Nagano A, Sugita K, Onishi S, Tabata Y, Kedoin C, et al. Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats. Pediatric Surgery International. 2024. doi:10.1007/s00383-024-05858-y

BibTeX
@article{Tsuruno2024,
  author = {Tsuruno, Yudai and Nagano, Ayaka and Sugita, Koshiro and Onishi, Shun and Tabata, Yumiko and Kedoin, Chihiro and Murakami, Masakazu and Yano, Keisuke and Kawano, Takafumi and Hasuzawa, Nao and Nomura, Masatoshi and Kaji, Tatsuru and Bitoh, Yuko and Ieiri, Satoshi},
  title = {Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats},
  journal = {Pediatric Surgery International},
  year = {2024},
  doi = {10.1007/s00383-024-05858-y}
}
Kostenlos starten →